Just read that TuHURA got FDA orphan drug status for IFx-2.0, a melanoma treatment that's designed to help patients who didn't respond to checkpoint inhibitors. Apparently the Phase 1 data looked pretty solid - good safety profile, no serious toxicity issues, and some patients who were resistant to the standard anti-PD-1 drugs actually showed clinical benefit when they tried this.

The orphan designation is interesting because it opens up some real advantages for them - seven years of market exclusivity, tax credits, research grants, and they don't have to pay the standard FDA user fee. That's a pretty meaningful runway for a smaller biotech company.

They've also got a Phase 3 trial running with IFx-2.0 combined with Keytruda for advanced Merkel cell carcinoma, so there's more data coming. Stock was trading at $0.5351 when I checked, down about 4.6% from the previous close. Curious to see how this orphan status plays out for them over the next couple years.